Alzheimer's disease treated patients showed different patterns for oxidative stress and inflammation markers

Food and Chemical Toxicology

Volumn 61, Issue , 2013, Pages 209-214

  Gubandru, Miriana ^a   Margina, Denisa ^a   Tsitsimpikou, Christina ^b   Goutzourelas, Nikos ^c   Tsarouhas, Konstantinos ^d,e   Ilie, Mihaela ^a   Tsatsakis, Aristidis Michael ^d   Kouretas, Demetrios ^c  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b General Chemical State Laboratory   (Greece)

^c UNIVERSITY OF THESSALY   (Greece)

^d UNIVERSITY OF CRETE   (Greece)

^e General Hospital of Karditsa   (Greece)

Author keywords

Alzheimer's disease; Biomarkers; Endothelial dysfunction; Inflammation; Oxidative stress

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CARBONYL DERIVATIVE; DONEPEZIL; DONEPEZIL PLUS MEMANTINE; GLUTATHIONE; GLUTATHIONE REDUCTASE; HOMOCYSTEINE; INTERLEUKIN 6; MALONALDEHYDE; N(G),N(G) DIMETHYLARGININE; RIVASTIGMINE; TUMOR NECROSIS FACTOR ALPHA;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; INFLAMMATION; MALE; OXIDATIVE STRESS; VENOUS BLOOD;

2,2-DIPHENYL-1-PICRYLHYDRAZYL; 2,4-DINITROPHENYLHYDRAZINE; AD; ADMA; ADVANCED GLYCATION END-PRODUCTS; AGES; ALZHEIMER'S DISEASE; ALZHEIMER'S DISEASES; ASYMMETRIC DYMETHYLARGININE; BH(2); BH(4); BIOMARKERS; CARDIOVASCULAR DISEASE; CRBNLS; CVD; DDAHS; DIHYDROBIOPTERIN; DIMETHYLARGININE DIMETHYLAMINOHYDROLASES; DNPH; DPPH; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENOS; GSH; INFLAMMATION; MALONDIALDEHYDE; MDA; N-METHYL-D-ASPARTATE-TYPE GLUTAMATE RECEPTORS; NITRIC OXIDE SYNTHASE; NMDARS; NOS; OXIDATIVE STRESS; PROTEIN CARBONYLS; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; REDUCED GLUTATHIONE; RNS; ROS; TAC; TBA; TBARS; TETRAHYDROBIOPTERIN; THIOBARBITURIC ACID; THIOBARBITURIC ACID REACTIVE SPECIES; TOTAL ANTIOXIDANT CAPACITY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIOXIDANTS; ARGININE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; GLUTATHIONE; HOMOCYSTEINE; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; OXIDATIVE STRESS; PROTEIN CARBONYLATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84888847391     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2013.07.013     Document Type: Article

References (47)

1. Arlt S., Schulze F., Eichenlaub M., Maas R., Lehmbeck J.T., Schwedhelm E., Jahn H., Böger R.H. Asymmetrical dimethylarginine is increased in plasma and decreased in cerebrospinal fluid of patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2008, 26(1):58-64.
2. Bomboi G., Castello L., Cosentino F., Giubilei F., Orzi F., Volpe M. Alzheimer's disease and endothelial dysfunction. Neurol. Sci. 2010, 31(1):1-8.
3. Brennan A.M., Suh S.W., Won S.J., Narasimhan P., Kauppinen T.M., Lee H., Edling Y., Chan P.H., Swanson R.A. NADPH oxidase is the primary source of superoxide induced by NMDA receptor activation. Nat. Neurosci. 2009, 12:857-863.
4. Cho D.H., Nakamura T., Fang J., Cieplak P., Godzik A., Gu Z., Lipton S.A. S-Nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury. Science 2009, 324(5923):102-105.
5. Chu L.W. Alzheimer's disease: early diagnosis and treatment. Hong Kong Med. J. 2012, 18:228-237.
6. Collins T. Endothelial nuclear factor-kappa B and the initiation of the atherosclerotic lesion. Lab. Invest. 1993, 68:499-508.
7. Cummings J.L. Alzheimer's disease. N. Engl. J. Med. 2004, 351:56-67.
8. Dumont M., Beal F. Neuroprotective strategies involving ROS in Alzheimer's disease. Free Radical Biol. Med. 2011, 51(5):1014-1026.
9. Dumont M., Ho D.J., Calingasan N.Y., Xu H., Gibson G., Beal M.F. Mitochondrial dihydrolipoyl succinyltransferase deficiency accelerates amyloid pathology and memory deficit in a transgenic mouse model of amyloid deposition. Free Radical Biol. Med. 2009, 47:1019-1027.
10. Feng Y., Wang X. Antioxidant Therapies for Alzheimer's Disease. Oxid. Med. Cell. Longevity 2012, 2012:472932. 10.1155/2012/4729321-17.
11. Furukawa-Hibi Y., Alkam T., Nitta A., Matsuyama A., Mizoguchi H., Suzuki K., Moussaoui S., Yu Q.S., Greig N.H., Nagai T., Yamada K. Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-β peptide in mice. Behav. Brain Res. 2011, 225:222-229.
12. Hansson Petersen C.A., Alikhani N., Behbahani H., Wiehager B., Pavlov P.F., Alafuzoff I., Leinonen V., Ito A., Winblad B., Glaser E., Ankarcrona M. The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc. Natl. Acad. Sci. USA 2008, 105:13145-13150.
13. Hensley K., Hall N., Subramaniam R., Cole P., Harris M., Aksenov M., Aksenova M., Gabbita S.P., Wu J.F., Carney J.M. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J. Neurochem. 1995, 65:2146-2156.
14. Hirose J., Yamabe S., Takada K., Okamoto N., Nagai R., Mizuta H. Immunohistochemical distribution of advanced glycation end products (AGEs) in human osteoarthritic cartilage. Acta Histochem. 2011, 113(6):613-618.
15. Inanaga K., Ichiki T., Miyazaki R., Takeda K., Hashimoto T., Matsuura H., Sunagawa K. Acetylcholinesterase inhibitors attenuate atherogenesis in apolipoprotein E-knockout mice. Atherosclerosis 2010, 213(1):52-58.
16. Kalaria R.N., Maestre G.E., Arizaga R., et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol. 2008, 7(9):812-826.
17. Keller J.N., Pang Z., Geddes J.W., Begley J.G., Germeyer A., Waeg G., Mattson M.P. Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid beta-peptide: role of the lipid peroxidation product 4-hydroxynonenal. J. Neurochem. 1997, 69(1):273-284.
18. Landim M.B.P., Filho A.C., Palandri Chagas A.C. Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis. Clinics 2009, 64(5):471-478.
19. Lin M.T., Beal M.F. Alzheimer's APP mangles mitochondria. Nat. Med. 2006, 12(11):1241-1243.
20. Lipton S.A. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat. Rev. Drug Discov. 2006, 5(2):160-170.
21. Liu, W., Xu, Z., Deng, Y., Xu, B., Wei, Y., Yang, T., 2013. Protective effects of memantine against methylmercury-induced glutamate dyshomeostasis and oxidative stress in rat cerebral cortex, neurotox. res., doi: 10.1007/s12640-013-9386-3 (Epub ahead of print).
22. Lovell M.A., Markesbery W.R. Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease. Nucl. Acids Res. 2007, 35(22):7497-7504.
23. Mancuso M., Orsucci D., Siciliano G., Murri L. Mitochondria, mitochondrial DNA and Alzheimer's disease. What comes first?. Curr. Alzheimer Res. 2008, 5(5):457-468.
24. Manczak M., Anekonda T.S., Henson E., Park B.S., Quinn J., Reddy P.H. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum. Mol. Genet. 2006, 15(9):1437-1449.
25. Mao P., Reddy P.H. Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer's Disease: implications for early intervention and therapeutics. Biochim. Biophys. Acta 2011, 1812(11):1359-1370.
26. Margina D., Gradinaru D., Panaite C., Cimponeriu D., Vladica M., Danciulescu R., Mitrea N. The association of adipose tissue markers for redox imbalance and the cardio-vascular risk in obese patients. HealthMED 2011, 5:194-199.
27. McGrath L.T., McGleenon B.M., Brennan S., McColl D., McIlroy S., Passmore A.P. Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde. QJM 2001, 94(9):485-490.
28. Nakamura T., Lipton S.A. Redox modulation by S-nitrosylation contributes to protein misfolding, mitochondrial dynamics, and neuronal synaptic damage in neurodegenerative diseases. Cell Death Differ. 2011, 18:1478-1486.
29. Nizri E., Irony-Tur-Sinai M., Faranesh N., Lavon I., Lavi E., Weinstock M., Brenner T. Suppression of neuroinflammation and immunomodulation by the acetylcholinesterase inhibitor rivastigmine. J. Neuroimmunol. 2008, 203(1):12-22.
30. Nunomura R.J., Castellani R.J., Zhu X., Moreira P.I., Perry G., Smith M.A. Involvement of oxidative stress in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2006, 65(7):631-641.
31. Patsoukis N., Georgiou C.D. Determination of the thiol redox state of organisms: new oxidative stress indicators. Anal. Bioanal. Chem. 2004, 378(7):1783-1792.
32. Puca A.A., Carrizzo A., Villa F., Ferrario A., Casaburo M., Maciag A., Vecchione C. Vascular aging: the role of oxidative stress. Int. J. Biochem. Cell Biol. 2013, 45(3):556-559.
33. Reddy Y.N., Murthy S.V., Krishna D.R., Prabhakar M.C. Role of free radicals and antioxidants in tuberculosis patients. Indian J. Tuberc 2004, 51:213-218.
34. Saxena G., Singh S.P., Agrawal R., Nath C. Effect of donepezil and tacrine on oxidative stress in intracerebral streptozotocin-induced model of dementia in mice. Eur. J. Pharmacol. 2008, 581(3):283-289.
35. Sebeková K., Podracká L., Blazícek P., Syrová D., Heidland A., Schinzel R. Plasma levels of advanced glycation end products in children with renal disease. Pediatr. Nephrol. 2001, 16:1105-1112.
36. Selley M.L. Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer's disease. Neurobiol. Aging 2003, 24(7):903-907.
37. Shenk J.C., Liu J., Fischbach K., Xu K., Puchowicz M., Obrenovich M.E., Gasimov E., Alvarez L.M., Ames B.N., Lamanna J.C., Aliev G. The effect of acetyl-L-carnitine and R-alpha-lipoic acid treatment in ApoE4 mouse as a model of human Alzheimer's disease. J. Neurol. Sci. 2009, 283:199-206.
38. Shifrin H., Nadler-Milbauer M., Shoham S., Weinstock M. Rivastigmine alleviates experimentally induced colitis in mice and rats by acting at central and peripheral sites to modulate immune responses. PLoS One 2013, 8(2):e57668. 10.1371/journal.pone.0057668.
39. Smith R.A., Murphy M.P. Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann. NY Acad. Sci. 2009, 1201:96-103.
40. Spindler M., Beal M.F., Henchcliffe C. Coenzyme Q10 effects in neurodegenerative disease. Neuropsychiatr. Dis. Treat. 2009, 5:597-610.
41. Teerlink T., Luo Z., Palm F., Wilcox C.S. Cellular ADMA: regulation and action. Pharmacol. Res. 2009, 60(6):448-460.
42. Veskoukis A.S., Tsatsakis A.M., Kouretas D. Dietary oxidative stress and antioxidant defense with an emphasis on plant extract administration. Cell Stress Chaperon 2012, 17(1):11-21.
43. Veskoukis A.S., Nikolaidis M.G., Kyparos A., Kokkinos D., Nepka C., Barbanis S., Kouretas D. Effects of xanthine oxidase inhibition on oxidative stress and swimming performance in rats. Appl. Physiol. Nutr. Metab. 2008, 33(6):1140-1154.
44. Vlassara H., Cai W., Chen X., Serrano E.J., Shobha M.S., Uribarri J., Woodward M., Striker G.E. Managing chronic inflammation in the aging diabetic patient with CKD by diet or sevelamer carbonate: a modern paradigm shift. J. Gerontol. A Biol. Sci. Med. Sci. 2012, 67(12):1410-1416.
45. Walsh D.M., Selkoe D.J. Aβ oligomers - adecade of discovery. J. Neurochem. 2007, 101(5):1172-1184.
46. Yan S.F., Ramasamy R., Naka Y., Schmidt A.M. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circulat. Res. 2003, 93:1159-1169.
47. Yoshiyama Y., Kojima A., Ishikawa C., Arai K. Anti-inflammatory action of donepezil ameliorates tau pathology, synaptic loss, and neurodegeneration in a tauopathy mouse model. J. Alzheimers Dis. 2010, 22(1):295-306.